Research Article
Upadacitinib Is a Better Choice than Abrocitinib for Patients with Moderate-to-Severe Atopic Dermatitis: An Updated Meta-Analysis
Table 1
Characteristics of studies included in the meta-analysis.
| | Author year | Publication type | Intervention (inhibitor type) | Exposure | Comparator | Number | Age | Sex (male/female) | Disease duration (years) | End of treatment | Funding |
| | Simpson et al. 2020 [12] | Multicentre III-RCT (NCT03349060) | Abrocitinib | 100 mg (n = 156) | Placebo (n = 77) | 387 | 100 mg: 32.6 ± 15.4 | 100 mg: 90/66 | 100 mg: 24.9 ± 16.1 | 12 weeks | Pfizer Inc | | 200 mg (n = 154) | 200 mg: 33.0 ± 17.4 | 200 mg: 81/73 | 200 mg: 22.7 ± 14.5 | | Placebo: 31.5 ± 14.4 | Placebo: 49/28 | Placebo: 22.5 ± 14.4 |
| | Sliverberg et al. 2020 [13] | Multicentre III-RCT (NCT03575871) | Abrocitinib | 100 mg (n = 158) | Placebo (n = 78) | 391 | 100 mg: 37.4 ± 15.8 | 100 mg: 94/64 | 100 mg: 21.1 ± 14.8 | 12 weeks | Pfizer Inc | | 200 mg (n = 155) | 200 mg: 33.5 ± 14.7 | 200 mg: 88/67 | 200 mg: 20.5 ± 14.8 | | Placebo: 33.4 ± 13.8 | Placebo: 47/31 | Placebo: 21.7 ± 14.3 |
| | Gooderham et al. 2019 [11] | Multicentre II-RCT (NCT02780167) | Abrocitinib | 10 mg (n = 49) | Placebo (n = 55) | 267 | 10 mg: 44.3 ± 15.9 | 10 mg: 21/28 | 10 mg: 30.2 (1.8–60.6) | 12 weeks | Pfizer Inc | | 30 mg (n = 50) | 30 mg: 37.6 ± 15.9 | 30 mg: 22/29 | 30 mg: 20.5 (1.2–66.6) | | 100 mg (n = 55) | 100 mg: 41.1 ± 15.6 | 100 mg: 31/25 | 100 mg: 23.8 (1.1–66.7) | | 200 mg (n = 54) | 200 mg: 38.7 ± 17.6 | 200 mg: 28/27 | 200 mg: 19.6 (1.9–68.8) | | Placebo: 42.6 ± 15.1 | Placebo: 21/35 | Placebo: 25.6 (1.1–67.1) |
| | Bieber et al. 2021 [14] | Multicentre III-RCT (NCT03720470) | Abrocitinib | 100 mg (n = 238) | Placebo (n = 131) | 838 | 100 mg: 37.3 ± 14.8 | 100 mg: 120/118 | 100 mg: 22.7 ± 16.3 | 16 weeks | Pfizer Inc | | 200 mg: 38.8 ± 14.5 | 200 mg: 104/122 | 200 mg: 23.4 ± 15.6 | | 200 mg (n = 226) | 300 mg: 37.1 ± 14.6 | 300 mg: 108/134 | 300 mg: 22.8 ± 14.8 | | Placebo: 37.4 ± 15.2 | Placebo: 77/54 | Placebo: 21.4 ± 14.4 |
| | Guttman-Yassky et al. 2020 [15] | Multicentre IIB-RCT (NCT02925117) | Upadacitinib | 7.5 mg (n = 42) | Placebo (n = 41) | 167 | 7.5 mg: 41.5 ± 15.4 | 7.5 mg: 28/14 | 7.5 mg: 30.4 ± 18.1 | 16 weeks | AbbVie Inc | | 15 mg (n = 42) | 15 mg: 38.5 ± 15.2 | 15 mg: 30/12 | 15 mg: 22.6 ± 15.8 | | 30 mg (n = 42) | 30 mg: 39.9 ± 15.3 | 30 mg: 22/20 | 30 mg: 24.2 ± 13.6 | | Placebo: 39.9 ± 17.5 | Placebo: 17/24 | Placebo: 26.8 ± 18.8 |
| | Guttman-Yassky et al. 2021 [16] (1) | Multicentre III-RCT (NCT03569293) | Upadacitinib | 15 mg (n = 281) | Placebo (n = 281) | 847 | 15 mg: 34.1 (12–74) | 15 mg: 157/124 | 15 mg: 20.5 ± 15.9 | 16 weeks | AbbVie Inc | | 30 mg (n = 285) | 30 mg: 33.6 (12–75) | 30 mg: 155/130 | 30 mg: 20.4 ± 14.3 | | Placebo: 34.4 (12–75) | Placebo: 144/137 | Placebo: 21.3 ± 15.3 |
| | Guttman-Yassky et al. 2021 [16] (2) | Multicentre III-RCT (NCT03607422) | Upadacitinib | 15 mg (n = 276) | Placebo (n = 278) | 836 | 15 mg: 33.3 (12–74) | 15 mg: 155/121 | 15 mg: 18.8 ± 13.3 | 16 weeks | AbbVie Inc | | 30 mg (n = 282) | 30 mg: 34.1 (12–75) | 30 mg: 162/120 | 30 mg: 20.8 ± 14.3 | | Placebo: 33.4 (13–71) | Placebo: 154/124 | Placebo: 21.1 ± 13.6 |
| | Reich et al. 2021 [17] | Multicentre III-RCT (NCT03568318) | Upadacitinib | 15 mg (n = 300) | Placebo (n = 304) | 901 | 15 mg: 32.5 (13–74) | 15 mg: 179/121 | 15 mg: 22.9 ± 13.9 | 16 weeks | AbbVie Inc | | 30 mg (n = 297) | 30 mg: 35.5 (12–72) | 30 mg: 190/107 | 30 mg: 23.1 ± 16.1 | | Placebo: 34.3 (12–75) | Placebo: 178/126 | Placebo: 24.3 ± 15.2 |
|
|
Results of both RCTs were published in the same study. |
